Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 28:17:5.
doi: 10.1186/s12962-019-0174-7. eCollection 2019.

Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Noga Gershon  1 , Yakir Berchenko  1 , Peter S Hall  2 , Daniel A Goldstein  3   4
Affiliations

Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Noga Gershon et al. Cost Eff Resour Alloc. .

Abstract

Background: Breast cancer is the second most common cancer worldwide, the most common among women, and the most frequent cause of death among women in less developed regions. Trastuzumab is a humanized monoclonal antibody that downregulates the extracellular domain of the HER2 protein. Using trastuzumab to treat women with localized HER2-positive breast cancer has been shown to improve survival. The objective of this study is to explore the cost-effectiveness of adjuvant trastuzumab, from a societal perspective, in 11 African countries. In addition, we aimed to establish value-based prices for trastuzumab based on the gross domestic product per capita in each country.

Methods: We developed a Markov model in order to assess the costs and benefits associated with trastuzumab treatment over a lifetime horizon. A probabilistic sensitivity analysis was performed in order to estimate the impact of uncertainty of parameter-values on the results. Efficacy inputs were derived using clinical trial data from non-African countries.

Results: In the base case analysis, trastuzumab yielded a gain ranging from 0.92 LYs in Nigeria to 1.07 LYs in South Africa, and 0.9 QALYs in Nigeria to 1.02 QALYs in South Africa. The incremental cost ranged from 19,561 USD in Nigeria to 19,997 USD in Congo, and an incremental cost-effectiveness ratio ranging from 19,534 USD/QALY in South Africa to 21,697 USD/QALY in Nigeria. Using willingness to pay estimates based on World Health Organization recommendations, trastuzumab appear to not be cost-effective in all countries analyzed. Cost-effectiveness estimates were most sensitive to the discount rate, trastuzumab cost, and the hazard ratio.

Conclusions: Trastuzumab does not appear to be cost effective in the African countries analyzed. In order for trastuzumab to be cost-effective, the costs of treatment would require significant discounts.

Keywords: Cost-effectiveness; Sub-Saharan Africa; Trastuzumab.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Markov model structure
Fig. 2
Fig. 2
Sensitivity analysis results
Fig. 3
Fig. 3
Estimated treatment price in all examined countries compatible with value-based price (1 GDP per capita)
Fig. 4
Fig. 4
Estimated treatment price in all examined countries compatible with value-based price (3 GDP per capita)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parkin D, Bray F, Devesa S. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37:4–66. doi: 10.1016/S0959-8049(01)00267-2. - DOI - PubMed
    1. Kingham TP. Series cancer control in Africa 3 treatment of cancer in sub-Saharan Africa. Lancet Oncol. 2013;14:e158–e167. doi: 10.1016/S1470-2045(12)70472-2. - DOI - PubMed
    1. Institute of Medicine. Cancer control opportunities in low- and middle-income countries. vol 57. 2007. https://www.ncbi.nlm.nih.gov/books/NBK54030/pdf/Bookshelf_NBK54030.pdf. Accessed Sept 14 2017.
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol. 2007;18:1493–1499. doi: 10.1093/annonc/mdm185. - DOI - PubMed